In a study to better understand how to treat inflammatory bowel disease at the Weizmann Institute of Science. Led by the group of Prof. Eran Elinav of the Systems Immunology Department, in collaboration with the Molecular Genetics Department’s Prof. Rotem Sorek and a Weizmann spinoff company - BiomX Inc., published their findings in the prestigious journal Cell.

BiomX Inc. is a clinical-stage microbiome company advancing novel phage therapies that target specific pathogenic bacteria. Their new approach uses special phages to target and destroy unwanted and harmful bacteria in the gut, with the research results under exclusive license from Yeda Research & Development.

Prof. Eran Elinav commented: " To our knowledge, this constitutes the first ‘silver bullet’ approach promising a precise suppression of disease-causing gut microbes, without harming the surrounding microbiome."

Participating in the study from Prof. Eran Elinav’s lab was Dr. Sara Federici, Rafael Valdés Mas, and Denise Kviatcovsky, along with Dr. Sharon Kredo-Russo from BiomX and other researchers.